Reportedly, Pfizer is holding the company’s COVID-19 antiviral therapy Paxlovid under tight control. This is a disappointment to numerous investigators who want to test the antiviral combination therapy with other drugs in case the virus develops resistance to the combo.

The U.S. Food and Drug Administration indirectly refuted Pfizer’s recommendation that it’s all right for COVID-19 patients to take another round of Paxlovid if they experience a rebound after completing the first course.

Less than three months after Swedish Orphan Biovitrum AB (Sobi) agreed to be acquired by Advent International and GIC Special Investments for nearly $8 billion, the deal fell through after AstraZeneca withheld the company’s 8 percent stake from the buyout offer.

Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.

Moderna is seeking to invalidate two patents belonging to Arbutus Biopharma that deal with drug-delivery technology.

Teva Pharmaceutical Industries temporarily halted drug production at the company’s Irvine plant in California to address issues raised by the U.S. Food and Drug Administration after a recent inspection, the company said on Oct. 4.

The U.S. Food and Drug Administration is leaning toward authorizing half-dose booster shots of the Moderna Inc. Covid-19 vaccine, Bloomberg News reported on Sept. 28, citing people familiar with the matter.

U.S. President Joe Biden’s administration ruled out nominating Janet Woodcock as the permanent head of the Food and Drug Administration, Bloomberg News reported on Aug. 19, citing people familiar with the matter.

Moderna Chief Executive Officer Stéphane Bancel sees significant growth opportunities for his company and messenger RNA-based vaccines.

Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies (SPAC) that will be focused on taking biotech companies public.